New Autophagy Activator AA-20 Extends Worm Lifespan Without Blocking mTOR

Autophagy—the cellular recycling system that delivers damaged proteins, lipid droplets, and other debris to lysosomes—declines with age and its impairment is a hallmark of diseases from neurodegeneration to metabolic disorders. Most pharmacological autophagy activators (rapamycin, metformin, spermidine, urolithin A) work by inhibiting mTORC1, a master nutrient sensor that also governs protein synthesis and immune function, creating significant off-target liability. Finding compounds that activate autophagy via mTOR-independent mechanisms has therefore become a priority in aging and disease research.

To address this, the research team conducted a phenotypic screen of one million small-molecule candidates, selecting compounds that accelerated lipid droplet clearance without cytotoxicity and without suppressing S6 kinase phosphorylation—a proxy for mTORC1 activity. AA-20 emerged as a lead compound. The study then systematically characterized AA-20's mechanism and biological effects across human cell lines and the nematode C. elegans, a well-validated model for longevity research.

In human cells, AA-20 enhanced autophagic flux and promoted lipid droplet clearance. In C. elegans, the compound reduced neutral lipid accumulation and significantly decreased polyglutamine protein aggregation—both effects were abolished in atg-3 autophagy-deficient mutants, confirming that these outcomes are autophagy-dependent. Healthspan metrics improved, including better movement and stress resistance. Critically, AA-20 extended wild-type nematode lifespan but failed to do so in autophagy-deficient animals, establishing a causal link between autophagy induction and the longevity benefit.

Mechanistically, AA-20 appears to act at least partly through HLH-30, the C. elegans ortholog of TFEB—a transcription factor that drives expression of autophagy and lysosomal biogenesis genes. Knockdown of hlh-30 blocked most AA-20-induced phenotypes, including lifespan extension. Importantly, AA-20 did not suppress mTORC1 signaling (measured by S6K phosphorylation), suggesting it activates TFEB/HLH-30 through a parallel pathway, potentially involving calcium signaling or Protein Kinase B rather than canonical mTOR inhibition.

These findings position AA-20 as a novel class of autophagy activator with a distinct mechanism of action. Its ability to clear both protein aggregates and lipid droplets without mTOR suppression makes it a compelling candidate for therapeutic development targeting age-related proteinopathies (e.g., Huntington's, Parkinson's disease) and lipid storage disorders such as fatty liver disease, while potentially avoiding the immunosuppression associated with rapamycin-class drugs.